Literature DB >> 29710183

An Update on the Management of Neonatal Brachial Plexus Palsy-Replacing Old Paradigms: A Review.

Brandon W Smith1, Alecia K Daunter2, Lynda J-S Yang1, Thomas J Wilson3.   

Abstract

Importance: Neonatal brachial plexus palsy (NBPP) can result in persistent deficits for those who develop it. Advances in surgical technique have resulted in the availability of safe, reliable options for treatment. Prevailing paradigms include, "all neonatal brachial plexus palsy recovers," "wait a year to see if recovery occurs," and "don't move the arm." Practicing by these principles places these patients at a disadvantage. Thus, the importance of this review is to provide an update on the management of NBPP to replace old beliefs with new paradigms. Observations: Changes within denervated muscle begin at the moment of injury, but without reinnervation become irreversible 18 to 24 months following denervation. These time-sensitive, irreversible changes are the scientific basis for the recommendations herein for the early management of NBPP and put into question the old paradigms. Early referral has become increasingly important because improved outcomes can be achieved using new management algorithms that allow surgery to be offered to patients unlikely to recover sufficiently with conservative management. Mounting evidence supports improved outcomes for appropriately selected patients with surgical management compared with natural history. Primary nerve surgery options now include nerve graft repair and nerve transfer. Specific indications continue to be elucidated, but both techniques offer a significant chance of restoration of function. Conclusions and Relevance: Mounting data support both the safety and effectiveness of surgery for patients with persistent NBPP. Despite this support, primary nerve surgery for NBPP continues to be underused. Surgery is but one part of the multidisciplinary care of NBPP. Early referral and implementation of multidisciplinary strategies give these children the best chance of functional recovery. Primary care physicians, nerve surgeons, physiatrists, and occupational and physical therapists must partner to continue to modify current treatment paradigms to provide improved quality care to neonates and children affected by NBPP.

Entities:  

Mesh:

Year:  2018        PMID: 29710183     DOI: 10.1001/jamapediatrics.2018.0124

Source DB:  PubMed          Journal:  JAMA Pediatr        ISSN: 2168-6203            Impact factor:   16.193


  6 in total

Review 1.  Elbow flexion in neonatal brachial plexus palsy: a meta-analysis of graft versus transfer.

Authors:  Muhibullah S Tora; Nathan Hardcastle; Pavlos Texakalidis; Jeremy Wetzel; Joshua J Chern
Journal:  Childs Nerv Syst       Date:  2019-03-28       Impact factor: 1.475

Review 2.  Novel Uses of Nerve Transfers.

Authors:  Thomas J Wilson
Journal:  Neurotherapeutics       Date:  2019-01       Impact factor: 7.620

3.  Knowledge of neonatal brachial plexus palsy among medical professionals in North America.

Authors:  Molly M McNeely; Kate Wan-Chu Chang; Brandon W Smith; Denise Justice; Alecia K Daunter; Lynda J-S Yang; John E McGillicuddy
Journal:  Childs Nerv Syst       Date:  2021-08-18       Impact factor: 1.475

4.  Single Blind Randomized Controlled Trial of Modified Constraint-Induced Movement Therapy in Infants With the Sequelas of Unilateral Brachial Plexus Injury.

Authors:  Zhenzhen Cui; Le Liu; Xi Chen; Haiyan Zeng; Shizhu Zheng
Journal:  Front Hum Neurosci       Date:  2022-05-30       Impact factor: 3.473

5.  Conjoint muscle transfer and subscapularis slide in brachial plexus birth palsy: Clinical outcomes in shoulder functions.

Authors:  Sanjay Maurya; P S Bhandari; Surya Chaitanya
Journal:  Med J Armed Forces India       Date:  2020-08-05

6.  MiR-615 Agomir Encapsulated in Pluronic F-127 Alleviates Neuron Damage and Facilitates Function Recovery After Brachial Plexus Avulsion.

Authors:  Kangzhen Chen; Lu Ding; Hua Shui; Yinru Liang; Xiaomin Zhang; Tao Wang; Linke Li; Shuxian Liu; Hongfu Wu
Journal:  J Mol Neurosci       Date:  2021-09-26       Impact factor: 3.444

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.